Drug Trial Radar · NCT02857998
A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms
Last checked: Nov 19, 2026Latest source record: Jul 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
134
Actual
Start
Dec 27, 2016
Primary completion
Jun 30, 2021
Study completion Sep 30, 2021
Sponsor
- Lead sponsor
- Hutchison Medipharma LimitedIndustry
- Sponsor type
- Industry
- First posted
- Aug 5, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms
Conditions
- Mature B-cell Neoplasms
Interventions
HMPL-523Drug
Oral administration, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limited toxicities evaluated with NCI CTCAE v4.03Time frame: within 28 days after the first dose
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Hospital
Shanghai, China
BeijingCancer Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.